Mérieux Développement, the investment arm of the French biotech conglomerate Institut Mérieux, has led a $6.4m financing round for NeuroPhage, a life sciences company. Existing investors Shire Pharmaceuticals also joined the round, which takes the total funding raised by the company to $35m. Neurophage is developing treatments for neurodegenerative diseases, including Alzheimer’s, Parkinson’s and Huntington’s diseases, and will use this latest round to continue its research. The firm raised $7m in series A funding in 2008 from an undisclosed group of private biotech investors. Shire Pharmaceuticals, an Irish-headquartered biopharmaceutical company, joined a $12.4m series B round in 2011, which was also led by Mérieux Développement. In 2012, that series B round was extended by a further $9m, with Mérieux and Shire joined by unnamed private investors.
Sectors
- News & Analysis
- Home
- Global Corporate Venturing
- Global University Venturing
- Latest News
- Publications
- Podcast
- Deal Data
- Video
- Subscribe
- Newsletters
- Community & Events
NeuroPhage builds with $6.4m investment
May 13, 2013 • Pete Guest
LEADERSHIP SOCIETY
Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.Featured Content
FUNDING ROUND DATA Which corporates are backing which startups? Search our corporate deal database.FUNDING ROUND DATA
Which corporates are backing which startups? Search our corporate deal database.
About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.